CD133+ and CD133− rhabdomyosarcoma cells were isolated and injected into immunodeficient NOD/SCID mice and the CD133+ cells showed tumor growth at lower numbers of injected cells, 102 versus 106, although only 1 mouse out of each cohort of 4 grew tumor at the lower dilutions of CD133+ cells, 102 and 103. This evidence concerns the gene PROM1 and neoplasm.